Parexel International Allies with Mortara Instrument
Parexel International is enhancing its early-phase cardiac safety capabilities through a new alliance with Mortara Instrument, a worldwide manufacturer and distributor of ECG devices and related technology based in Milwaukee, WI. Specifically, Parexel will supplement its ECG equipment with Mortara Instrument's Surveyor Telemetry Central System, which is already in use at the company's Baltimore, MD, early phase clinical unit.
"This relationship represents our commitment to providing comprehensive early phase cardiovascular expertise and capabilities, such as intensive ECG and thorough QT/QTc studies, supported by enabling technologies,” said Michelle Middle, Parexel's corporate VP and worldwide head of early phase, in a company press release.
Mortara's high-tech solution will automate the process of acquiring and recording ECGs for Parexel, which are wirelessly transmitted from devices worn by clinical trial participants.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
